Analytical Data
-
Gene name
VEGF145
-
简介
VEGF145 Protein is a subtype of Vascular Endothelial Growth Factor A (VEGF-A). VEGF-A is a key member of the VEGF family of cytokines that can promote neovascularization and increase vascular permeability. VEGF145 Protein, Human (HEK293) is the recombinant human-derived VEGF145 protein, expressed by HEK293 , with tag free. The total length of VEGF145 Protein, Human (HEK293) is 145 a.a., with molecular weight of ~16.92 kDa.
- Application
-
Alternative Names
VEGF-AA; MVCD1; VAS; Vascular endothelial growth factor A; VEGF; VPF
-
Species
Human
-
Source
HEK293
-
Tag
Tag Free
-
Purity
Greater than 95% as determined by reducing SDS-PAGE.
-
Uniprot
P15692-6
-
Expression Region
A27-R171
-
Protein Length
Partial
-
Molecular Weight
19-23 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
VEGF145, a recombinant protein derived from the vascular endothelial growth factor (VEGF) family, has garnered significant attention in recent years due to its role in angiogenesis and vascular permeability. Angiogenesis, the formation of new blood vessels, is a critical process in various physiological and pathological conditions, including wound healing, cancer progression, and chronic inflammatory diseases. VEGF145 is specifically engineered to enhance the biological activity of native VEGF, potentially offering greater therapeutic benefits in conditions characterized by inadequate angiogenesis. Research has demonstrated that VEGF145 can effectively stimulate endothelial cell proliferation and migration, crucial for new blood vessel formation. Furthermore, its augmented binding affinity to VEGF receptors suggests it may improve therapeutic outcomes in diseases requiring enhanced vascularization, such as ischemic heart disease and peripheral vascular disorders. As the understanding of VEGF signaling pathways and the mechanisms of action of VEGF145 advances, studies are increasingly focusing on its application in regenerative medicine and targeted cancer therapies. The potential of VEGF145 to modulate the tumor microenvironment and promote healthy tissue regeneration heightens its relevance in developing novel treatment strategies that harness the body's natural ability to repair and regenerate tissues. The ongoing research into VEGF145 continues to reveal promising avenues for clinical applications, making it an exciting subject of study in the field of biomedical science.
